The Opus Genetics, Inc. (Nasdaq: IRD) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other filings that document material events, financing transactions, and clinical or regulatory milestones. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, and its filings offer detailed insight into these activities.
Through its Form 8-K filings, the company reports material agreements and financings, such as securities purchase agreements for registered direct offerings of common stock and pre-funded warrants, including the use of proceeds to advance its LCA5 and BEST1 gene therapy clinical programs. These filings may also describe the terms of pre-funded warrants, closing conditions, and related legal opinions. Additional 8-Ks furnish press releases that announce financial results, cash position, and collaboration revenue, providing context on how Opus Genetics funds its research and development operations.
Regulation FD disclosures and other events reported in SEC filings frequently cover clinical and regulatory developments, including positive data from the OPGx-LCA5 Phase 1/2 trial, enrollment updates, and outcomes of FDA interactions such as Regenerative Medicine Advanced Therapy (RMAT) meetings. The company also uses 8-Ks to disclose inducement equity awards granted under its 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, these filings are paired with AI-powered summaries that help explain the key points of each document, from financing structures to trial design details. Users can review Opus Genetics’ quarterly and annual reports when available, as well as current reports and exhibits, to better understand its ophthalmic gene therapy pipeline, collaboration arrangements, and capital structure as described in its official SEC submissions.
Opus Genetics, Inc. filed a Form S-8 on September 26, 2025 to register securities under its 2020 Equity Incentive Plan. The filing incorporates by reference the company’s 2024 Annual Report (filed March 31, 2025), subsequent quarterly reports (filed May 15, 2025 and August 13, 2025) and multiple current reports filed between January 7, 2025 and September 2, 2025. The Registration Statement relies on prior effective S-8 registrations and includes customary exhibits and a power of attorney signed by management and directors.